PMID- 21707504
OWN - NLM
STAT- MEDLINE
DCOM- 20120529
LR  - 20220129
IS  - 1875-5992 (Electronic)
IS  - 1871-5206 (Linking)
VI  - 12
IP  - 1
DP  - 2012 Jan
TI  - Selective activation of intracellular signalling pathways in dendritic cells for 
      cancer immunotherapy.
PG  - 29-39
AB  - One of the major challenges in achieving effective anti-cancer immunotherapy is 
      to counteract immunological tolerance. Most tumor-associated antigens (TAAs) are 
      sensed as self. Hence, naturally occurring tolerance towards them has to be 
      overcome. Fortunately, there is increasing evidence that anti-tumor immune 
      responses occur and play a crucial role in the success of well-established 
      anti-neoplastic therapies such as radiotherapy and chemotherapy. In fact, their 
      effectiveness relies on signalling by pattern recognition receptors such as 
      Toll-like receptors (TLRs). TLR signal transduction involves activation of a few 
      well-known pathways, of which nuclear factor kappaB (NF-kappaB) and mitogen activated 
      protein kinases (MAPKs) are possibly the best characterized. Therefore, 
      constitutive activation of these pathways in immune cells can potentially enhance 
      anti-tumor immunity, especially when targeted to professional antigen presenting 
      cells (APCs) such as dendritic cells (DCs). Several strategies have been devised 
      to test this hypothesis, including constitutive activation of TLRs, NF-kappaB and 
      MAPKs (extracellular-signal regulated kinase (ERK), p38 and c-Jun kinase 1 
      (JNK1)). Activation of these pathways in mouse and human DCs has differential 
      effects in immunogenicity and in many cases, enhanced antitumor immunity in 
      pre-clinical models, establishing the basis for future clinical applications.
FAU - Arce, Frederick
AU  - Arce F
AD  - Windeyer Institute of Medical Sciences. 46 Cleveland Street, WT1 4JF London, 
      United Kingdom.
FAU - Kochan, Grazyna
AU  - Kochan G
FAU - Breckpot, Karine
AU  - Breckpot K
FAU - Stephenson, Holly
AU  - Stephenson H
FAU - Escors, David
AU  - Escors D
LA  - eng
GR  - 18433/ARC_/Arthritis Research UK/United Kingdom
GR  - 18433/VAC_/Versus Arthritis/United Kingdom
GR  - CAPMC/CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Anticancer Agents Med Chem
JT  - Anti-cancer agents in medicinal chemistry
JID - 101265649
RN  - 0 (Cytokines)
RN  - 0 (Toll-Like Receptors)
SB  - IM
MH  - Animals
MH  - Cytokines/immunology
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Immunotherapy/methods
MH  - Neoplasms/*immunology/*therapy
MH  - Signal Transduction
MH  - Toll-Like Receptors/immunology
EDAT- 2011/06/29 06:00
MHDA- 2012/05/30 06:00
CRDT- 2011/06/29 06:00
PHST- 2010/11/25 00:00 [received]
PHST- 2011/05/11 00:00 [revised]
PHST- 2011/06/01 00:00 [accepted]
PHST- 2011/06/29 06:00 [entrez]
PHST- 2011/06/29 06:00 [pubmed]
PHST- 2012/05/30 06:00 [medline]
AID - BSP/ACAMC/E-Pub/ 00194 [pii]
AID - 10.2174/187152012798764679 [doi]
PST - ppublish
SO  - Anticancer Agents Med Chem. 2012 Jan;12(1):29-39. doi: 
      10.2174/187152012798764679.